PhaseRx
Seattle
Washington
United States
28 articles about PhaseRx
-
PhaseRx Receives Decision From the Nasdaq Hearings Panel for Continued Listing of Shares
12/13/2017
PhaseRx today announced it received a decision from the Nasdaq Hearings Panel granting PhaseRx's request for continued listing on The Nasdaq Capital Market until January 31, 2018.
-
The company indicates it plans to continue to manage and operate under the bankruptcy filing while it works with Cowen and Company to develop a plan forward.
-
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL From EMA
11/28/2017
PhaseRx today announced that the EMA's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan medicinal product designation for PRX-ASL, for the treatment of ASLD, PhaseRx's second drug candidate to treat a urea cycle disorder.
-
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/9/2017
Total operating expenses for the third quarter of 2017 were $2.5 million, compared to $3.1 million of operating expenses in the third quarter of 2016.
-
PhaseRx Receives Delisting Notice From Nasdaq and Evaluates Listing Options
10/27/2017
PhaseRx today announced receipt of a delisting notice from Nasdaq, which informed the company that, absent an appeal, trading in PhaseRx's common stock will be suspended from Nasdaq at the opening of business on November 1, 2017.
-
PhaseRx has undertaken a strategic restructuring that includes the termination of 50 percent of its staff.
-
PhaseRx Receives Orphan Drug Designation From FDA For PRX-ASL For The Treatment Of Argininosuccinate Lyase Deficiency
9/21/2017
-
PhaseRx Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/10/2017
-
PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update
5/12/2017
-
PhaseRx Receives Positive Opinion For Orphan Drug Designation For PRX-OTC From EMA
4/25/2017
-
PhaseRx Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
3/27/2017
-
PhaseRx Receives Orphan Drug Designation From FDA For PRX-OTC For The Treatment Of Ornithine Transcarbamylase Deficiency
11/28/2016
-
PhaseRx Announces Positive Safety Results From Large Animal Study With Hybrid mRNA Delivery Technology
11/9/2016
-
PhaseRx Reports Third Quarter 2016 Financial Results And Provides Corporate Update
11/8/2016
-
PhaseRx To Present Company Overview At Upcoming Investor Conferences
10/11/2016
-
PhaseRx To Present At The 2016 Aegis Growth Conference
9/14/2016
-
PhaseRx Appoints Peggy Phillips To Board Of Directors
8/23/2016
-
PhaseRx Reports Second Quarter 2016 Financial Results And Provides Corporate Update
8/3/2016
-
PhaseRx Appoints Gordon Brandt, M.D. As Chief Medical Officer
7/20/2016
-
PhaseRx Announces Targeted mRNA Data Presentations At The Controlled Release Society Annual Meeting And Exposition
7/11/2016